TRENDFINDERS- Scanning Board for Charts and Stocks

[Trendfinders]

IDMI: 7:32AM IDM Pharma announces updated data from Mifamurtide Compassionate access program; data shows it is well-tolerated while showing signs of disease control (IDMI) 2.11 : The co announces the presentation of updated data from a compassionate access program evaluating mifamurtide in patients with lung metastases as a result of the progression of osteosarcoma, a rare and often fatal bone tumor that typically affects children and young adults. The data show that L-MTP-PE in combination with other therapies is safe, well- tolerated and exhibited signs of disease control.